First-Line Pembrolizumab Monotherapy for Advanced NSCLC With Programmed Death-Ligand 1 Expression Greater Than or Equal to 50%: Real-World Study Including Older Patients in Japan

por Goto, Yasushi, Tamura, Atsuhisa, Matsumoto, Hirotaka, Isobe, Kazutoshi, Ozaki, Tomohiro, Santorelli, Melissa L., Taniguchi, Kazuko, Kamitani, Tetsu, Irisawa, Masato, Kanda, Kingo, Abe, Machiko, Burke, Thomas, Nokihara, Hiroshi
Publicado 2022

Real-World Treatments and Clinical Outcomes in Advanced NSCLC without Actionable Mutations after Introduction of Immunotherapy in Japan

por Nokihara, Hiroshi, Kijima, Takashi, Yokoyama, Toshihide, Kagamu, Hiroshi, Suzuki, Takuji, Mori, Masahide, Santorelli, Melissa L., Taniguchi, Kazuko, Kamitani, Tetsu, Irisawa, Masato, Kanda, Kingo, Abe, Machiko, Burke, Thomas, Goto, Yasushi
Publicado 2022

Health Care Resource Use Among Patients with Advanced Non–Small Cell Lung Cancer in Japan, 2017–2019

por Goto, Yasushi, Kawamura, Kodai, Fukuhara, Tatsuro, Namba, Yukiko, Aoe, Keisuke, Shukuya, Takehito, Tsuda, Takeshi, Santorelli, Melissa L., Taniguchi, Kazuko, Kamitani, Tetsu, Irisawa, Masato, Kanda, Kingo, Abe, Machiko, Burke, Thomas, Nokihara, Hiroshi
Publicado 2023